161 related articles for article (PubMed ID: 20567006)
1. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Ingelsson E; Bratt O; Bill-Axelson A; Lambe M; Stattin P; Adolfsson J
J Clin Oncol; 2010 Jul; 28(21):3448-56. PubMed ID: 20567006
[TBL] [Abstract][Full Text] [Related]
2. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.
Otto SJ; Schröder FH; de Koning HJ
J Clin Oncol; 2006 Sep; 24(25):4184-9. PubMed ID: 16943535
[TBL] [Abstract][Full Text] [Related]
4. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden.
Robinson D; Garmo H; Lindahl B; Van Hemelrijck M; Adolfsson J; Bratt O; Holmberg L; Stattin P
Int J Cancer; 2012 Jan; 130(2):478-87. PubMed ID: 21387298
[TBL] [Abstract][Full Text] [Related]
5. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
[TBL] [Abstract][Full Text] [Related]
6. Occupation and cancer - follow-up of 15 million people in five Nordic countries.
Pukkala E; Martinsen JI; Lynge E; Gunnarsdottir HK; Sparén P; Tryggvadottir L; Weiderpass E; Kjaerheim K
Acta Oncol; 2009; 48(5):646-790. PubMed ID: 19925375
[TBL] [Abstract][Full Text] [Related]
7. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20-65 years.
van Dis I; Kromhout D; Geleijnse JM; Boer JM; Verschuren WM
Eur J Cardiovasc Prev Rehabil; 2009 Dec; 16(6):729-34. PubMed ID: 19809330
[TBL] [Abstract][Full Text] [Related]
8. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population.
Meisinger C; Döring A; Löwel H;
Eur Heart J; 2006 May; 27(10):1245-50. PubMed ID: 16611670
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
11. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; Nuver J; de Wit R; Gietema JA; ten Bokkel Huinink WW; Rodrigus PT; Schimmel EC; Aleman BM; van Leeuwen FE
J Clin Oncol; 2006 Jan; 24(3):467-75. PubMed ID: 16421423
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction.
Wattanakit K; Coresh J; Muntner P; Marsh J; Folsom AR
J Am Coll Cardiol; 2006 Sep; 48(6):1183-9. PubMed ID: 16979003
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis.
Kjaergaard AD; Ellervik C; Tybjaerg-Hansen A; Axelsson CK; Grønholdt ML; Grande P; Jensen GB; Nordestgaard BG
Circulation; 2007 Feb; 115(7):861-71. PubMed ID: 17309937
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cancer among patients with atopic dermatitis.
Hagströmer L; Ye W; Nyrén O; Emtestam L
Arch Dermatol; 2005 Sep; 141(9):1123-7. PubMed ID: 16172309
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
18. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
19. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
20. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Persson M; Hedblad B; Nelson JJ; Berglund G
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
